HemoSonics, LLC is breaking new ground in point-of-care Viscoelastic #hemostasis testing. When time is critical, the Quantra® QPlus® System offers rapid, accurate, and easy to understand results that enable clinicians to make more informed #transfusion decisions, more quickly. This novel, cartridge-based POC VET system now has De Novo marketing authorization in the USA and is intended to assess the coagulation status of perioperative patients at the point of care.
Follow us at @HemoSonics
Follow us at @HemoSonics
Location: United States, Virginia, Charlottesville
Employees: 51-200
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | UVA Licens... | lvg.virgin... |
Mentions in press and media 6
| Date | Title | Description |
| 26.10.2021 | What Innovation Works’ life sciences director sees for the industry’s future in Pittsburgh | Megan Shaw loves the excitement of the startup world. That enthusiasm would lead down a path toward boosting life science companies — and Pittsburgh. After advising companies as a consultant early in her career, “I decided that I really wan... |
| 23.10.2014 | Three of these nine innovative technologies are Ben Companies! | |
| 11.06.2013 | Diagnostic to assess clotting disorders in surgery raises new capital | Last fall, the Charlottesville, Virginia-based medical device company enlisted Cambridge Consultants to help it navigate each stage of development and get the device ready for large-scale clinical use, according to a company statement. The ... |
| 21.09.2012 | Diagnostic device uses ultrasound to assess risk of excessive bleeding, clots in clinical settings | Walker said the company will use the funding to finish product development and initiate clinical studies. The device, the size of an iMac, will be smaller when it goes into production, said Walker. HemoSonics will generate its main revenue ... |
| - | Diagnostic device uses ultrasound to assess risk of excessive bleeding, clots in clinical settings | A diagnostic device could speed up and take the guesswork out of diagnosing and guiding treatment for excessive bleeding and overactive clotting in clinical settings. A medical device company is raising $3.5 million to develop the device, w... |
| - | Diagnostic to assess clotting disorders in surgery raises new capital | A medical device company has raised nearly $1.3 million to advance a diagnostic to detect life-threatening bleeding and blood clots, according to a Form D filing with the U.S. Securities and Exchange Commission. HemoSonics‘ Point of Care An... |